Abstract: A system for assisting a rescuer in performing cardio-pulmonary resuscitation (CPR) on a patient includes: a proximity sensor configured to be positioned at a location corresponding to a location of a rescuer's hand when delivering compressions to a patient's chest, the proximity sensor configured to produce a signal indicative of the rescuer's hands being released from the patient's chest; a medical device operatively coupled with the proximity sensor and configured to provide resuscitative treatment to the patient; and a controller communicatively coupled with the medical device and the proximity sensor. The controller is configured to: determine, based upon the signal from the proximity sensor, if the rescuer's hands have been released from the patient's chest, and trigger an action by the medical device in response to a determination that the rescuer's hands have been released from the patient's chest.

Abstract: Methods and systems for team cooperation with real-time recording of one or more moment-associating elements. For example, a method includes: delivering, in response to an instruction, an invitation to each member of one or more members associated with a workspace; granting, in response to acceptance of the invitation by one or more subscribers of the one or more members, subscription permission to the one or more subscribers; receiving the one or more moment-associating elements; transforming the one or more moment-associating elements into one or more pieces of moment-associating information; and transmitting at least one piece of the one or more pieces of moment-associating information to the one or more subscribers.

Abstract: The present disclosure provides materials and methods for the continuous measurement of biomolecules in vivo and in real-time. The present disclosure relates more specifically to using capture agents and detection agents within a microfluidic device to detect and quantify biochemical features of biomarkers, enabling real-time detection and concentration measurements.

Abstract: This disclosure is directed to a process for producing a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that is water insoluble or poorly water soluble. The polymer is water soluble and comprises at least one first terminal group modified with H (H) or a hydrophobic moiety (C) and a second terminal group modified with a hydrophilic moiety. The polymer can be a modified symmetrically or asymmetrically branched polymers. This disclosure is further directed to a method for producing a polymer having a pre-defined H/C ratio.

Abstract: This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a targeting bioactive agent (TBA); a payload bioactive agent (PBA) covalently linked to the targeting bioactive agent (TBA) directly or indirectly; and, optionally, a polymer forming nanoaggregates. The pharmaceutical composition can comprise Ag+ tumor cytotoxicity to tumor cells having a tumor antigen (Ag+ tumor cells) and Ag? tumor cytotoxicity to tumor cells free from a tumor antigen (Ag? tumor cells). The pharmaceutical composition can be an antibody-drug conjugate (ADC) for treating cancers having tumor antigen positive (Ag+) tumor cells, tumor antigen negative (Ag?) tumor cells, or heterogenous cancers having both tumor antigen positive (Ag+) tumor cells and tumor antigen negative (Ag?) tumor cells.

Abstract: This disclosure is directed to a pharmaceutical composition comprising sodium bicarbonate and a polymer-drug nanoaggregate having a polymer and a taxane. The polymer is water soluble and comprises at least one first terminal group modified with a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. The taxane can include paclitaxel, docetaxel, cabazitaxel, larotaxel, milataxel, ortataxel, tesetaxel, derivatives therefrom or a combination thereof, which are water insoluble or poorly water soluble. Such polymer-drug nanoaggregates can improve drug solubility, stability, in vivo availability and efficacy, and reduce side effects such as renal toxicity. This invention is also directed to a process for producing the pharmaceutical composition comprising the polymer-drug nanoaggregate.

Abstract: Provided are a federated graph clustering method based on distributed graph embedding, a device, and a readable storage medium.

Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: For any application that processes speech, improving the quality of the feature vectors may improve the quality of the speech application. The quality of feature vectors may be improved by modifying a neural network architecture for computing feature vectors to allocate computational resources where they are more effective for learning and computing the feature vectors. Contextual feature vectors may be computed from feature vectors by using a parameterized downsampling operation that decreases a vector sequence rate, processing the downsampled vectors with a neural network, and using a parameterized upsampling operation that increases a vector sequence rate. For example, parameterized downsampling may decrease a vector sequence rate by a factor of two, a neural may require fewer computational resources since it operates with a lower vector sequence rate, and parameterized upsampling may then increase the vector sequence rate by a factor of two.

Abstract: Methods and systems for team cooperation with real-time recording of one or more moment-associating elements. For example, a method includes: delivering, in response to an instruction, an invitation to each member of one or more members associated with a workspace; granting, in response to acceptance of the invitation by one or more subscribers of the one or more members, subscription permission to the one or more subscribers; receiving the one or more moment-associating elements; transforming the one or more moment-associating elements into one or more pieces of moment-associating information; and transmitting at least one piece of the one or more pieces of moment-associating information to the one or more subscribers.

Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: A method includes: obtaining equipment sensor data from sensors in a time series; obtaining equipment optimization goal data from optimization goals in a time series; obtaining historical data on equipment abnormal events and intervention events; obtaining static equipment input parameters; applying time series model to the equipment sensor and optimization data, historical event data, and static equipment input parameters, to obtain predicted equipment sensor data; optimizing and controlling hardware operation based on the obtained predicted equipment sensor data; and providing predicted actions for abnormal event intervention based on the obtained predicted equipment sensor data.

Abstract: A system for assisting a rescuer in performing cardio-pulmonary resuscitation (CPR) on a patient includes: a proximity sensor configured to be positioned at a location corresponding to a location of a rescuer's hand when delivering compressions to a patient's chest, the proximity sensor configured to produce a signal indicative of the rescuer's hands being released from the patient's chest; a medical device operatively coupled with the proximity sensor and configured to provide resuscitative treatment to the patient; and a controller communicatively coupled with the medical device and the proximity sensor. The controller is configured to: determine, based upon the signal from the proximity sensor, if the rescuer's hands have been released from the patient's chest, and trigger an action by the medical device in response to a determination that the rescuer's hands have been released from the patient's chest.

Abstract: Apparatuses and corresponding methods are provided for determining molecular properties of a molecule. To determine molecular properties of the molecule, a molecule library comprising the molecule is generated, a focused library comprising the molecule is generated by filtering the molecule library; the focused library is attached to a flow cell of the imaging instrument; and a fluid control module of the imaging instrument is controlled to incubate the flow cell with a fluid comprising labelled target molecules. A light source module and an imaging module of the imaging instrument are operated in a selected operational mode such that the light source module illuminates the flow cell and the imaging module captures light generated by fluorescence by the labelled target molecules within the flow cell. Image data is generated based on the captured light and the imaging data is analyzed to determine molecular properties of the at least one molecule.

Abstract: This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that is water insoluble or poorly water soluble. The polymer is water soluble and comprises at least one first terminal group modified with H or a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. This disclosure is also directed to a method for treating or preventing a disease including one or more immune disorders, infectious diseases and cancers using the pharmaceutical composition disclosed herein. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

Abstract: Provided are a federated graph clustering method based on distributed graph embedding, a device, and a readable storage medium.

Abstract: Systems and methods are provided for enhancing the speech modality in a large language model (LLM) and for retaining in-context learning capabilities without overfitting to trained tasks. Systems obtain a first set of training data comprising tuples of a sample of speech combined with synthetically generated pairings of speech comprehension test questions and answers that correspond to the sample of speech and obtain a second set of training data comprising pairings of automatic speech recognition data. Systems generate and align a first set of encodings of the first set of training data and a second set of encodings of the second set of training data. Systems train the LLM on a greater amount of the first set of training data than the second set of training data and use the trained LLM to perform a natural language processing task.